{"id":"NCT04688320","sponsor":"Supergene, LLC","briefTitle":"Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE","officialTitle":"Multicenter, Open Label, Randomized Comparative Trial of the Efficacy and Safety of a Single Bolus Recombinant Non-immunogenic Staphylokinase and Bolus-infusion of Alteplase in Patients With Massive Pulmonary Embolism (FORPE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-15","primaryCompletion":"2023-07-27","completion":"2023-07-27","firstPosted":"2020-12-29","resultsPosted":"2025-04-02","lastUpdate":"2025-04-02"},"enrollment":310,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Massive Pulmonary Embolism"],"interventions":[{"type":"DRUG","name":"Recombinant nonimmunogenic staphylokinase","otherNames":["Fortelyzin"]},{"type":"DRUG","name":"Alteplase","otherNames":["Actillyze"]}],"arms":[{"label":"Recombinant nonimmunogenic staphylokinase","type":"EXPERIMENTAL"},{"label":"Alteplase","type":"EXPERIMENTAL"}],"summary":"Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the Alteplase in patients with massive pulmonary embolism","primaryOutcome":{"measure":"Death From All Causes","timeFrame":"within 7 days","effectByArm":[{"arm":"Recombinant Nonimmunogenic Staphylokinase","deltaMin":3,"sd":null},{"arm":"Alteplase","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":23,"countries":["Russia"]},"refs":{"pmids":["40391253"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":145},"commonTop":["Hematuria"]}}